Friday, July 10, 2026
🇺🇸 FDA

Drug profile · INN

plozasiran

REDEMPLO

plozasiran (REDEMPLO) is an FDA-listed pharmaceutical active ingredient. Associated with Arrowhead Pharmaceuticals Ireland Limited.

EMA: unknown Cardiovascular system (C10) C10AX
Patents linked 20
Pipeline programs 9
News articles 2
Drug details — plozasiran
Class
Cardiovascular system (C10)
Route
—
Patents
20
Programs
9
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

plozasiran (REDEMPLO) is an FDA-listed pharmaceutical active ingredient. Associated with Arrowhead Pharmaceuticals Ireland Limited.

Key facts

INN plozasiran
Brand REDEMPLO
Therapeutic class Cardiovascular system (C10)
ATC code C10AX
Originator Arrowhead Pharmaceuticals Ireland Limited

Approval history

Authority Status Date
EMA unknown —

Recent coverage

View all news
Plozasiran TGA Approval: REDEMPLO® Now Available in Australia for FCS
Critical impact NewsFamilial Chylomicronemia Syndrome (FCS)May 2, 2026

Plozasiran TGA Approval: REDEMPLO® Now Available in Australia for FCS

TGA · Familial Chylomicronemia Syndrome (FCS) · 6 min

Arrowhead Pharmaceuticals has secured TGA approval for REDEMPLO® (plozasiran) in Australia, marking a significant step in providing treatment options for patients with Familial Chylomicronemia Syndrome (FCS). This approval expands global access to the novel therapy for this rare genetic disorder.

Dr. Elena Rossi
Plozasiran TGA Approval in Australia for FCS Patients
High impact NewsFamilial Chylomicronemia Syndrome (FCS)May 2, 2026

Plozasiran TGA Approval in Australia for FCS Patients

TGA · Familial Chylomicronemia Syndrome (FCS) · 5 min

Arrowhead Pharmaceuticals has announced the Therapeutic Goods Administration (TGA) approval of REDEMPLO® (plozasiran) in Australia for patients with Familial Chylomicronemia Syndrome (FCS). This landmark decision broadens global access to a crucial treatment for this rare genetic disorder.

Dr. Amina Farouk

Pipeline programs

Search pipeline Sponsor programs
  1. ARO-APOC3 PFS, Plozasiran Injection Placebo Phase 3 · Arrowhead Pharmaceuticals Ireland · Severe hypertriglyceridemia (SHTG)
  2. ARO-APOC3 PFS, Plozasiran Injection Placebo Phase 3 · Arrowhead Pharmaceuticals Ireland · Hypertriglyceridemia
  3. Plozasiran Phase 3 · Arrowhead Pharmaceuticals Ireland · Familial Chylomicronemia
  4. Plozasiran Phase 3 · Arrowhead Pharmaceuticals Ireland · Severe Hypertriglyceridemia
  5. Plozasiran Phase 3 · Arrowhead Pharmaceuticals Ireland · Familial Chylomicronemia Syndrome
  6. Plozasiran Injection Phase 3 · Arrowhead Pharmaceuticals Ireland · Hypertriglyceridemia
  7. Plozasiran Injection Phase 3 · Arrowhead Pharmaceuticals Ireland · Severe Hypertriglyceridemia
  8. Plozasiran Injection Placebo, ARO-APOC3 PFS Phase 3 · Arrowhead Pharmaceuticals Ireland · Severe hypertriglyceridemia (SHTG)

Related & competitor drugs

Browse all drugs
  1. alirocumab Cardiovascular system (C10)
  2. aliskiren Cardiovascular system (C09)
  3. azilsartan medoxomil Cardiovascular system (C09)
  4. bempedoic acid Cardiovascular system (C10)
  5. bosentan Cardiovascular system (C02)
  6. dofetilide Cardiovascular system (C01)

Related patents

Browse patents Arrowhead Pharmaceuticals Ireland Limited patent hub

  1. US 12378558

    RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12365897

    RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of use

    Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12221610

    RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12173086

    Alpha-v beta-6 integrin ligands and uses thereof

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12116573

    Targeting ligands for therapeutic compounds

    Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12110492

    RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of use

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12065458

    Trialkyne linking agents and methods of use

    Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12054718

    RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and methods of use

    Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11920134

    Compositions and methods for inhibiting expression of RRM2 genes

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11845937

    RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11840688

    Compositions and methods for inhibiting gene expression of Hif2alpha

    Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11597701

    Integrin ligands and uses thereof

    Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11590156

    RNAi agents for hepatitis B virus infection

    Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11517584

    RNAi agents for Hepatitis B virus infection

    Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11492624

    RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1

    Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11214802

    RNAi agents for inhibiting expression of alpha-ENaC and methods of use

    Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11208662

    RNAi inhibition of alpha-ENaC expression

    Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11180529

    Alpha-v beta-6 integrin ligands and uses thereof

    Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10995335

    RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use

    Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10927373

    Compositions and methods for inhibiting gene expression of Hif2alpha

    Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is plozasiran?

plozasiran (REDEMPLO) is an FDA-listed pharmaceutical active ingredient. Associated with Arrowhead Pharmaceuticals Ireland Limited.

What is the brand name for plozasiran?

REDEMPLO is a marketed brand name for plozasiran. Check FDA Drugs@FDA for the current US label holder and prescribing information.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.